Insider Buying: Tharimmune, Inc. (NASDAQ:THAR) CEO Purchases 61,496 Shares of Stock

Tharimmune, Inc. (NASDAQ:THAR) CEO Sireesh Appajosyula purchased 61,496 shares of the company’s stock in a transaction on Friday, June 20th. The stock was acquired at an average price of $1.48 per share, with a total value of $91,014.08. Following the completion of the purchase, the chief executive officer now directly owns 64,868 shares in the company, valued at $96,004.64. This trade represents a 1,823.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tharimmune Stock Performance

NASDAQ THAR opened at $1.66 on Thursday. The company has a market capitalization of $4.42 million, a P/E ratio of -0.21 and a beta of 1.04. Tharimmune, Inc. has a one year low of $0.95 and a one year high of $6.39. The stock has a 50 day moving average price of $1.42 and a 200-day moving average price of $1.64.

Tharimmune (NASDAQ:THAR) last posted its earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.15).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Virtu Financial LLC bought a new stake in shares of Tharimmune, Inc. (NASDAQ:THAR) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned about 1.11% of Tharimmune as of its most recent filing with the Securities and Exchange Commission. 1.16% of the stock is currently owned by hedge funds and other institutional investors.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).